시장보고서
상품코드
1469204

연부 육종 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 치료 유형별, 최종사용자별, 지역별, 경쟁별(2019-2029년)

Soft Tissue Sarcoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 연부 육종 시장은 2023년에 13억 6,000만 달러로 평가되며, 2029년까지의 CAGR은 8.45%로, 예측 기간 중 강력한 성장이 예측됩니다.

연부 육종의 주요 치료법은 수술이며, 종양 또는 환부의 일부를 절제합니다. 방사선요법도 종양을 축소 또는 근절하기 위해 수술과의 병용 또는 단독 치료로서 채택되기도 합니다. 화학요법은 일반적으로 다른 치료법의 효과를 높이기 위한 보조요법으로 사용됩니다. 연부 육종의 예후는 암의 유형, 부위, 병기에 따라 크게 달라집니다. 일반적으로 조기 진단과 빠른 치료가 더 좋은 결과를 가져옵니다. 치료 옵션과 예후는 계속 발전하고 개선되고 있으므로 이 분야의 발전 상황을 파악하는 것이 매우 중요합니다. 임상시험은 최신 치료법을 접하고 연부 육종에 대한 최적의 접근 방식에 대한 더 많은 인사이트을 얻는 데 중요한 역할을 합니다. 연부 육종은 수술, 방사선 치료 및/또는 화학요법의 조합으로 효과적으로 치료할 수 있습니다. 연부 육종의 예후는 암의 유형, 부위, 병기 등 다양한 요인에 따라 달라집니다. 현재 진행 중인 임상시험과 연구는 치료 전략을 개선하고 치료 결과와 삶의 질을 향상시키기 위한 귀중한 정보를 제공합니다. 수술, 방사선 치료, 화학요법이 연부 육종의 가장 일반적인 치료법이지만, 면역요법, 분자표적치료, 한약과 같은 대체요법도 효과적입니다. 또한 식이요법과 운동요법을 포함한 생활습관 개선은 연부 육종 발병 위험을 줄이고 회복 과정을 돕는 데 도움이 될 수 있습니다.

주요 시장 촉진요인

암환자의 증가

새롭게 혁신적인 치료법의 개발

새로운 육종 치료제 승인 수의 증가

제휴 및 인수 등 주요 전략의 채택 증가

주요 시장이 해결해야 할 과제

치료비 상승

연부 육종 치료제의 부작용

주요 시장 동향

기타 치료법의 서론

헬스케어 의식의 향상

부문별 인사이트

치료 유형별 인사이트

최종사용자별 인사이트

지역별 인사이트

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 임상시험 분석

제6장 세계의 연부 육종 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 치료 유형별(표적치료, 화학요법, 혈관신생 저해제, 방사선요법, 기타)
    • 최종사용자별(병원, 재택의료, 전문 센터, 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵

제7장 북미의 연부 육종 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 치료 유형별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제8장 유럽의 연부 육종 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 치료 유형별
    • 최종사용자별
    • 국가별
  • 유럽 국가별 분석
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인

제9장 아시아태평양의 연부 육종 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 치료 유형별
    • 최종사용자별
    • 국가별
  • 아시아태평양 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제10장 남미의 연부 육종 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 치료 유형별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제11장 중동 및 아프리카의 연부 육종 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 치료 유형별
    • 최종사용자별
    • 국가별
  • MEA : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제12장 시장 역학

  • 촉진요인
  • 과제

제13장 시장 동향과 발전

  • 합병 매수(있는 경우)
  • 제품 출시(있는 경우)
  • 최근 동향

제14장 Porter's Five Forces 분석

  • 업계내의 경쟁
  • 신규 참여의 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제15장 경쟁 구도

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck Co., Inc.

제16장 전략적 제안

제17장 면책사항

KSA 24.05.17

Global Soft Tissue Sarcoma Market was valued at USD 1.36 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.45% through 2029. Surgery is typically the primary treatment approach for soft tissue sarcomas, involving the removal of the tumor or a portion of the affected area. Radiation therapy may also be employed to shrink or eradicate the tumor, either in combination with surgery or as a standalone treatment. Chemotherapy is commonly utilized as an adjunctive therapy to enhance the effectiveness of other treatment modalities. The prognosis for soft tissue sarcomas can vary significantly, contingent upon the type, location, and stage of the cancer. Generally, an earlier diagnosis and prompt treatment yield more favorable outcomes. It is crucial to remain up to date with advancements in the field, as treatment options and prognoses continue to evolve and improve. Clinical trials play a critical role in accessing state-of-the-art treatments and gaining further insights into optimal approaches for soft tissue sarcomas. Participation in clinical trials can contribute to improved outcomes and enhanced quality of life for patients with soft tissue sarcomas.Soft tissue sarcomas can be effectively treated by a blend of surgery, radiation therapy, and/or chemotherapy.Prognosis for soft tissue sarcomas depends on various factors, including the type, location, and stage of the cancer. Ongoing clinical trials and research provide valuable information to refine treatment strategies and enhance outcomes and quality of life. While surgery, radiation therapy, and chemotherapy are the most common treatments for soft tissue sarcomas, alternative options such as immunotherapy, targeted therapy, and herbal medicine have demonstrated efficacy in managing the condition. Also, lifestyle modifications, including dietary adjustments and exercise, can help reduce the risk of developing soft tissue sarcomas and assist in the recovery process.

Key Market Drivers

Increase in Cancer Cases

Sarcoma is a type of cancer that can affect various tissues. Soft tissue sarcomas specifically impact the connective, supportive, or surrounding tissues of the body's systems. According to the American Society of Clinical Oncology (ASCO), soft tissue sarcomas account for approximately 1% of all adult cancers. Although more prevalent in children, comprising around 15% of all childhood cancers, it remains a significant concern. Besides, the National Cancer Institute estimates that in 2019, approximately 12,750 cases of soft tissue sarcoma were diagnosed in the United States, with an estimated 5,270 resulting in death. In addition, the American Cancer Society reported approximately 3,600 new cases of bone and joint cancer in 2020, with 2,120 cases among males and 1,480 among females in the United States. On top of that, an estimated 1,720 deaths in the U.S. in 2020 were attributed to bone and joint cancer. Looking ahead, the American Cancer Society projects that approximately 13,590 new cases of soft tissue sarcoma will be diagnosed in 2024. Of these, 7,700 cases are expected among males and 5,890 among females in the United States. It is estimated that around 5,200 individuals (2,760 males and 2,440 females) will succumb to soft tissue sarcomas, according to the same source.

Development of New and Innovative Therapies

The development of new and innovative therapies is playing a crucial role in boosting the growth of the Soft Tissue Sarcoma (STS) market. Soft tissue sarcomas are a diverse group of rare cancers that develop in the connective tissues of the body, including muscles, fat, blood vessels, and nerves. Historically, treatment options for STS have been limited, but advancements in research and the introduction of novel therapies are changing the landscape. The introduction of new therapies, such as targeted therapies, immunotherapies, and precision medicine approaches, provides patients with a broader range of treatment options beyond traditional approaches like surgery, radiation, and chemotherapy. Innovative therapies are designed to specifically target the underlying genetic and molecular characteristics of STS tumors. This personalized approach can lead to improved patient outcomes, including better response rates and longer survival. Advanced diagnostics and biomarker testing enable the identification of specific mutations or genetic markers that guide treatment decisions. This allows for more individualized and effective treatment plans. Advances in understanding the genetic mutations driving STS have led to the development of targeted therapies that specifically inhibit the signaling pathways responsible for tumor growth.

Rise In the Number of Product Approval for New Sarcoma Drugs

The increase in the number of approved products for new sarcoma drugs has contributed to the growth of the sarcoma drugs market. For example, in May 2020, Bristol Myers Squibb, a pharmaceutical company, announced the approval of Pomalyst (pomalidomide) by the U.S. Food and Drug Administration (FDA). This approval was specifically for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or for patients with Kaposi sarcoma who are HIV-negative.

The approval of new sarcoma drugs adds diversity to the available treatment options. Different types of STS require tailored approaches, and a broader range of approved drugs enables healthcare providers to choose the most suitable treatment for each patient. New drugs that demonstrate efficacy in clinical trials can lead to improved survival rates and disease control, positively impacting the overall prognosis for STS patients. The approval of new sarcoma drugs encourages pharmaceutical companies and researchers to invest in innovative research, which can lead to the development of even more effective treatments. Regulatory approval allows a broader patient population to access the newly approved drugs, reaching more patients in need of effective therapies.

Rise In Adoption of Key Strategies Such as Collaboration and Acquisition

The rise in adoption of key strategies, such as collaboration, acquisition, agreement, and partnership, by the sarcoma drugs industry is driving the growth of the market. For example, in March 2021, Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, announced a clinical development collaboration with AgonOx, Inc. The collaboration aims to develop novel T cell-based cancer immunotherapies using Phio's lead INTASYL-based product candidate, PH-762, and AgonOx's "double positive" (DP) tumor-infiltrating lymphocyte (TIL) technology. Collaborative efforts can lead to the exploration of combination therapies, where different companies contribute complementary treatment approaches that, when combined, yield more effective results. Partnering with or acquiring companies with advanced technologies can lead to the development of innovative drug delivery methods, diagnostic tools, and personalized treatment approaches.

Collaboration can expedite research efforts by allowing companies to share data, insights, and resources. This accelerates the identification of potential targets and the development of new therapies. Collaborative efforts can lead to larger and more diverse clinical trials, which provide a more comprehensive evaluation of the safety and efficacy of potential STS treatments. Companies that collaborate or acquire specialized partners may benefit from streamlined regulatory pathways, leading to faster approvals and market entry for new therapies.

Key Market Challenges

High Cost of Treatments

High treatment costs can limit patient access to effective therapies, especially for individuals without adequate insurance coverage or financial resources. This can lead to delayed or suboptimal treatment, negatively impacting patient outcomes. The high out-of-pocket costs associated with STS treatments can place a significant financial burden on patients and their families, potentially leading to financial hardship and reduced quality of life. High treatment costs can attract public and regulatory scrutiny, leading to pricing pressure and potential limitations on reimbursement and coverage. The substantial costs associated with treatment methods hinder market growth. Several treatments for this disease are expensive, posing challenges for individuals, particularly those in rural areas. Consequently, this becomes a significant obstacle for the market. The rising expenses of radiotherapy and chemotherapy might impede the growth of the soft tissue sarcoma treatment market in the forecast period.

Side-Effects of Soft Tissue Sarcoma Drugs

The presence of significant side effects associated with Soft Tissue Sarcoma (STS) drugs can hinder the growth of the STS market. Side effects can impact patient quality of life, influence treatment decisions, and contribute to challenges in patient adherence and acceptance of treatments. Severe side effects can lead to decreased patient quality of life, affecting their ability to perform daily activities, work, and engage in social interactions. This can discourage patients from pursuing or continuing treatment. Patients experiencing intolerable side effects might choose to discontinue treatment prematurely, potentially reducing the effectiveness of the therapy and hindering positive treatment outcomes. Elderly or frail patients might be more susceptible to side effects, limiting the use of certain drugs in this population and potentially reducing the market demand.

Key Market Trends

Introduction of Other Therapies

The availability of many therapies offers healthcare providers a broader range of options to tailor treatment plans based on the specific subtype, stage, and characteristics of each patient's STS. With a variety of therapies to choose from, physicians can personalize treatment approaches, optimizing the chance of positive responses and minimizing adverse effects. Different STS subtypes have varying responses to treatments. The introduction of multiple therapies can help address unmet medical needs for subtypes that lack effective treatment options. A multitude of therapies can lead to better patient outcomes, including increased survival rates, enhanced quality of life, and better management of disease-related symptoms. The availability of many therapies encourages healthy market competition among pharmaceutical companies, leading to innovation, price competition, and improved treatment quality. For over four decades, the cornerstone of localized sarcoma treatment has involved surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after completing surgical resection, approximately 50.0% of patients with intermediate or high-grade sarcoma develop metastatic disease. The advent of targeted therapy has brought about a paradigm shift in the treatment approach for sarcoma. Targeted therapies and upcoming breakthroughs in the pipeline will continue to play a pivotal role in driving market growth throughout the forecast period.

Rising Healthcare Awareness

There is a growing awareness among patients and healthcare providers regarding the incidence of liposarcoma. Both patients and doctors are actively engaging in learning about the available therapies for treating these severe diseases, leading to increased market opportunities. Increased awareness prompts patients to seek medical attention at earlier stages of the disease, leading to timely diagnosis and treatment initiation. Early detection can result in better treatment outcomes and potentially higher survival rates. Patients and healthcare providers who are more informed about available therapies can make more educated treatment decisions, leading to improved patient management and adherence to treatment plans. The increasing awareness about the incidence of liposarcoma among patients and healthcare providers creates a ripple effect that positively impacts diagnosis, treatment, research, advocacy, and market growth. As more attention is focused on this rare cancer, opportunities arise for collaboration, innovation, and improved patient care within the liposarcoma market.

Segmental Insights

Treatment Type Insights

The segment of anti-angiogenesis drugs is projected to experience rapid growth during the forecast period. This can be attributed to the growing demand for these drugs in cancer treatment. The prevalence of cancer and the necessity for effective therapies are driving factors behind this segment. Anti-angiogenesis drugs employ a molecular approach to hinder the formation of new blood vessels, which are essential for tumor growth and spread. This approach shows promise due to its relatively lower side effects compared to chemotherapy and radiation. In addition, the advent of innovative cancer treatments like immunotherapy and gene therapy is expected to contribute to the expansion of the anti-angiogenesis drugs segment. As these treatments become more accessible, the demand for anti-angiogenesis drugs is anticipated to rise. Plus, the increasing demand for personalized medicines is likely to create new opportunities for segment growth. However, the high cost of these treatments may impose limitations on the expansion of the anti-angiogenesis drugs segment.

End User Insights

Based on the end user segmentation, the market is categorized into hospitals, homecare, specialty centers, and others. The hospitals segment held the largest market share in 2023 and is projected to maintain its dominance throughout the forecast period. This can be attributed to increased government expenditure aimed at the development of the healthcare sector. Hospitals offer comprehensive treatment facilities for soft tissue sarcoma patients, including diagnostic imaging, surgical intervention, chemotherapy, radiation therapy, and supportive care services. These facilities allow for multidisciplinary collaboration among oncologists, surgeons, radiologists, pathologists, and other healthcare professionals, ensuring that patients receive integrated and coordinated care across all stages of their treatment journey.

Hospitals play a central role in the management of soft tissue sarcomas by providing specialized expertise, comprehensive treatment facilities, advanced medical technologies, access to clinical trials and research, and supportive care services. As a result, they are the primary setting where patients with soft tissue sarcomas receive diagnosis, treatment, and ongoing care, making hospitals the dominant end-user in the Global Soft Tissue Sarcoma Market.

Regional Insights

The demand for soft tissue sarcomas in North America is projected to experience substantial growth during the forecast period. This can be attributed to the rising incidence of this cancer type in the region, coupled with the availability of advanced treatment options. Likewise, the increasing emphasis on research and development of innovative therapies, including immunotherapies and targeted therapies, is anticipated to propel the demand for soft tissue sarcomas in North America. Also, the growing prevalence of personalized medicines and the presence of improved healthcare infrastructure in the region are expected to further drive the demand. However, it is important to note that the high cost of treatments may act as a limiting factor for the growth of this segment in the region.

Key Market Players

F. Hoffmann-La Roche Ltd.

Mylan N.V.

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

Pfizer Inc.

GSK plc

Novartis AG

Bayer AG

Sun Pharmaceutical Industries Ltd.

Merck Co., Inc.

Report Scope:

In this report, the Global Soft Tissue Sarcoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Soft Tissue Sarcoma Market,By Treatment Type:

  • Targeted Therapy
  • Chemotherapy
  • Anti-Angiogenesis Drugs
  • Radiation Therapy
  • Others

Soft Tissue Sarcoma Market,By End User:

  • Hospitals
  • Homecare
  • Specialty Centres
  • Others

Soft Tissue Sarcoma Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Soft Tissue Sarcoma Market.

Available Customizations:

Global Soft Tissue Sarcoma marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validations
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Clinical Trial Analysis

  • 5.1.Ongoing Clinical Trials
  • 5.2.Completed Clinical Trials
  • 5.3.Terminated Clinical Trials
  • 5.4.Breakdown of Pipeline, By Development Phase
  • 5.5.Breakdown of Pipeline, By Status
  • 5.6.Breakdown of Pipeline, By Study Application
  • 5.7.Breakdown of Pipeline, By Region
  • 5.8.Clinical Trials Heat Map

6.Global Soft Tissue Sarcoma Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others)
    • 6.2.2.By End User (Hospitals, Homecare, Specialty Centres, Others)
    • 6.2.3.By Region
    • 6.2.4.By Company (2023)
  • 6.3.Market Map

7.North America Soft Tissue Sarcoma Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.ByTreatment Type
    • 7.2.2.By End User
    • 7.2.3.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States Soft Tissue Sarcoma Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Treatment Type
        • 7.3.1.2.2.By End User
    • 7.3.2.Canada Soft Tissue Sarcoma Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Treatment Type
        • 7.3.2.2.2.By End User
    • 7.3.3.Mexico Soft Tissue Sarcoma Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Treatment Type
        • 7.3.3.2.2.By End User

8.Europe Soft Tissue Sarcoma Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Treatment Type
    • 8.2.2.By End User
    • 8.2.3.By Country
  • 8.3.Europe: Country Analysis
    • 8.3.1.Germany Soft Tissue Sarcoma Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Treatment Type
        • 8.3.1.2.2.By End User
    • 8.3.2.United Kingdom Soft Tissue Sarcoma Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Treatment Type
        • 8.3.2.2.2.By End User
    • 8.3.3.Italy Soft Tissue Sarcoma Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Treatment Type
        • 8.3.3.2.2.By End User
    • 8.3.4.France Soft Tissue Sarcoma Market Outlook
      • 8.3.4.1.Market Size Forecast
        • 8.3.4.1.1.By Value
      • 8.3.4.2.Market Share Forecast
        • 8.3.4.2.1.By Treatment Type
        • 8.3.4.2.2.By End User
    • 8.3.5.Spain Soft Tissue Sarcoma Market Outlook
      • 8.3.5.1.Market Size Forecast
        • 8.3.5.1.1.By Value
      • 8.3.5.2.Market Share Forecast
        • 8.3.5.2.1.By Treatment Type
        • 8.3.5.2.2.By End User

9.Asia-Pacific Soft Tissue Sarcoma Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Treatment Type
    • 9.2.2.By End User
    • 9.2.3.By Country
  • 9.3.Asia-Pacific: Country Analysis
    • 9.3.1.China Soft Tissue Sarcoma Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Treatment Type
        • 9.3.1.2.2.By End User
    • 9.3.2.India Soft Tissue Sarcoma Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Treatment Type
        • 9.3.2.2.2.By End User
    • 9.3.3.Japan Soft Tissue Sarcoma Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Treatment Type
        • 9.3.3.2.2.By End User
    • 9.3.4.South Korea Soft Tissue Sarcoma Market Outlook
      • 9.3.4.1.Market Size Forecast
        • 9.3.4.1.1.By Value
      • 9.3.4.2.Market Share Forecast
        • 9.3.4.2.1.By Treatment Type
        • 9.3.4.2.2.By End User
    • 9.3.5.Australia Soft Tissue Sarcoma Market Outlook
      • 9.3.5.1.Market Size Forecast
        • 9.3.5.1.1.By Value
      • 9.3.5.2.Market Share Forecast
        • 9.3.5.2.1.By Treatment Type
        • 9.3.5.2.2.By End User

10.South America Soft Tissue Sarcoma Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Treatment Type
    • 10.2.2.By End User
    • 10.2.3.By Country
  • 10.3.South America: Country Analysis
    • 10.3.1.Brazil Soft Tissue Sarcoma Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Treatment Type
        • 10.3.1.2.2.By End User
    • 10.3.2.Argentina Soft Tissue Sarcoma Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Treatment Type
        • 10.3.2.2.2.By End User
    • 10.3.3.Colombia Soft Tissue Sarcoma Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Treatment Type
        • 10.3.3.2.2.By End User

11.Middle East and Africa Soft Tissue Sarcoma Market Outlook

  • 11.1.Market Size Forecast
    • 11.1.1.By Value
  • 11.2.Market Share Forecast
    • 11.2.1.By Treatment Type
    • 11.2.2.By End User
    • 11.2.3.By Country
  • 11.3.MEA: Country Analysis
    • 11.3.1.South Africa Soft Tissue Sarcoma Market Outlook
      • 11.3.1.1.Market Size Forecast
        • 11.3.1.1.1.By Value
      • 11.3.1.2.Market Share Forecast
        • 11.3.1.2.1.By Treatment Type
        • 11.3.1.2.2.By End User
    • 11.3.2.Saudi Arabia Soft Tissue Sarcoma Market Outlook
      • 11.3.2.1.Market Size Forecast
        • 11.3.2.1.1.By Value
      • 11.3.2.2.Market Share Forecast
        • 11.3.2.2.1.By Treatment Type
        • 11.3.2.2.2.By End User
    • 11.3.3.UAE Soft Tissue Sarcoma Market Outlook
      • 11.3.3.1.Market Size Forecast
        • 11.3.3.1.1.By Value
      • 11.3.3.2.Market Share Forecast
        • 11.3.3.2.1.By Treatment Type
        • 11.3.3.2.2.By End User

12.Market Dynamics

  • 12.1.Drivers
  • 12.2.Challenges

13.Market Trends Developments

  • 13.1.Merger Acquisition (If Any)
  • 13.2.Product Launches (If Any)
  • 13.3.Recent Developments

14.Porters Five Forces Analysis

  • 14.1.Competition in the Industry
  • 14.2.Potential of New Entrants
  • 14.3.Power of Suppliers
  • 14.4.Power of Customers
  • 14.5.Threat of Substitute Products

15.Competitive Landscape

  • 15.1.F. Hoffmann-La Roche Ltd.
    • 15.1.1.Business Overview
    • 15.1.2.Company Snapshot
    • 15.1.3.Products Services
    • 15.1.4.Financials (As Reported)
    • 15.1.5.Recent Developments
    • 15.1.6.Key Personnel Details
    • 15.1.7.SWOT Analysis
  • 15.2.Mylan N.V.
  • 15.3.Teva Pharmaceutical Industries Ltd.
  • 15.4.Sanofi S.A.
  • 15.5.Pfizer Inc.
  • 15.6.GSK plc
  • 15.7.Novartis AG
  • 15.8.Bayer AG
  • 15.9.Sun Pharmaceutical Industries Ltd.
  • 15.10.Merck Co., Inc.

16.Strategic Recommendations

17.About Us Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제